ArticleBioinorganic chemistry and applications2008
Synthesis, characterization, and in vitro cytotoxic activities of benzaldehyde thiosemicarbazone derivatives and their palladium (II) and platinum (II) complexes against various human tumor cell lines.
Article in Bioinorganic chemistry and applications, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 51 citations in OpenAlex.
- Crystal Design, Antitumor Activity and Molecular Docking of Novel Palladium(II) and Gold(III) Complexes with a Thiosemicarbazone Ligand.International journal of molecular sciences · 2023Article
- Microwave-assisted synthesis and antitumor evaluation of a new series of thiazolylcoumarin derivatives.EXCLI journal · 2017Article
- Synthesis and Characterization of New Palladium(II) Thiosemicarbazone Complexes and Their Cytotoxic Activity against Various Human Tumor Cell Lines.Bioinorganic chemistry and applications · 2013Article
- Novel platinum(II) and palladium(II) complexes of thiosemicarbazones derived from 5-substitutedthiophene-2-carboxaldehydes and their antiviral and cytotoxic activities.European journal of medicinal chemistry · 2011Article
- Antineoplastic Activity of New Transition Metal Complexes of 6-Methylpyridine-2-carbaldehyde-N(4)-ethylthiosemicarbazone: X-Ray Crystal Structures of [VO(2)(mpETSC)] and [Pt(mpETSC)Cl].Bioinorganic chemistry and applications · 2010Article
- cis-Bis[1-allyl-3-(2-pyrid-yl-κN)thio-ureato-κS]palladium(II).Acta crystallographica. Section E, Structure reports online · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The palladium (II) bis-chelate Pd (L(1-3))(2) and platinum (II) tetranuclear Pt(4)(L(4))(4) complexes of benzaldehyde thiosemicarbazone derivatives have been synthesized, and characterized by elemental analysis and IR, FAB(+)-mass and NMR ((1)H, (13)C) spectroscopy. The complex Pd(L(2))(2) [HL(2) = m-CN-benzaldehyde thiosemicarbazone] shows a square-planar geometry with two deprotonated ligands (L) coordinated to Pd(II) through the nitrogen and sulphur atoms in a transarrangement, while the complex Pt(4)(L(4))(4) [HL(4) = 4-phenyl-1-benzaldehyde thiosemicarbazone] has a tetranuclear geometry with four tridentate ligands coordinated to four Pt(II) ions through the carbon (aromatic ring), nitrogen, and sulphur atoms where the ligands are deprotonated at the NH group. The in vitro antitumor activity of the ligands and their complexes was determined against different human tumor cell lines, which revealed that the palladium (II) and platinum (II) complexes are more cytotoxic than their ligands with IC(50) values at the range of 0.07-3.67 microM. The tetranuclear complex Pt(4)(L(4))(4), with the phenyl group in the terminal amine of the ligand, showed higher antiproliferative activity (CI(50) = 0.07-0.12 microM) than the other tested palladium (II) complexes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.